Sex-specific role of myostatin signaling in neonatal muscle growth, denervation atrophy, and neuromuscular contractures
- Department of Medical Sciences, University of Cincinnati College of Medicine, United States
- Division of Orthopaedic Surgery, Cincinnati Children’s Hospital Medical Center, United States
- The Jackson Laboratory, United States
- Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, United States
- Department of Orthopaedic Surgery, University of Cincinnati College of Medicine, United States
- Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, United States
Figures
Figure 1 with 1 supplement
Pharmacologic inhibition of myostatin (MSTN) enhances neonatal skeletal muscle growth.
(A) Schematic depiction of ACVR2B-Fc treatment to inhibit MSTN in neonatal mice prior to and after unilateral brachial plexus injury (NBPI) at P5. Representative MicroCT images in (B) transverse and three-dimensional views revealed increased growth of non-denervated brachialis muscles in both female and male mice following 4 weeks of pharmacologic MSTN inhibition with ACVR2B-Fc. Quantitative analyses of (C) cross-sectional area and (D) whole-muscle volume in control brachialis muscles confirmed that neonatal MSTN inhibition enhances skeletal muscle growth. Neonatal MSTN inhibition further enhances (F) muscle weight and (G) total protein content of non-denervated biceps muscles in both sexes. Despite this, the increases in (E) muscle volume, and (H) muscle weight and protein levels were larger in females than males when compared to their respective DPBS controls. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (C, D, F, G) two-way analysis of variance (ANOVA) for sex and treatment with a Bonferroni correction for multiple comparisons, (E, H) unpaired two-tailed Student’s t-tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bar: 1000 µm.
Figure 1—figure supplement 1
Off-target effects of pharmacologic myostatin (MSTN) inhibition.
(A) MSTN inhibition does not alter protein levels in normally innervated biceps when normalized to muscle weight. Treatment with ACVR2B-Fc (B) does not promote additional weight gains in male mice, but instead, attenuates skeletal growth of non-denervated forelimbs and (D) reduces heart size. In contrast, ACVR2B-Fc treatment (E) reduces spleen size only in female mice. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (A–E) two-way analysis of variance (ANOVA) for sex and treatment with a Bonferroni correction for multiple comparisons. *p < 0.05, ***p < 0.001, ****p < 0.0001.
Figure 2 with 1 supplement
Pharmacologic myostatin (MSTN) inhibition reduces denervation-induced muscle atrophy in neonatal female mice.
Representative MicroCT images in (A) transverse and three-dimensional views revealed larger denervated brachialis muscles in female mice following MSTN inhibition. Quantitative analyses of (B) brachialis cross-sectional area and (C) whole-muscle volume confirmed MSTN inhibition reduces denervation-induced atrophy only in female mice. This partial rescue in growth of the denervated brachialis muscles is accompanied by increased (D) muscle weight and (E) total protein content of denervated biceps muscles in female mice only. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (B–E) two-way analysis of variance (ANOVA) for sex and treatment with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar: 1000 µm.
Figure 2—figure supplement 1
Effect of pharmacologic myostatin (MSTN) inhibition on normalized protein levels and skeletal growth in denervated forelimb.
(A) MSTN inhibition does not alter protein levels in denervated biceps when normalized to muscle weight. (B) Treatment with ACVR2B-Fc attenuates skeletal growth of denervated forelimbs only in male mice. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (A, B) two-way analysis of variance (ANOVA) for sex and treatment with a Bonferroni correction for multiple comparisons. *p < 0.05, ***p < 0.001, ****p < 0.0001.
Figure 3 with 1 supplement
Pharmacologic myostatin (MSTN) inhibition reduces neonatal denervation-induced contractures in neonatal female mice.
(A) Representative images of denervated (neonatal brachial plexus injury, NBPI) and contralateral forelimbs, and quantitation of both (B) elbow joint extension range of motion and (C) contracture severity revealed that MSTN inhibition reduces the formation of elbow flexion contractures after 4 weeks of neonatal denervation in female, but not male mice. Similarly, (D) representative images of bilateral forelimbs, and quantitation of both (E) shoulder joint external rotation range of motion and (F) contracture severity demonstrated improvements in shoulder rotation only in female mice. In (C, F), elbow and shoulder contracture severity is calculated as the difference in passive elbow extension and shoulder rotation, respectively, between the NBPI side and the contralateral side. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (B, E) three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons, (C, F) two-way ANOVA for sex and treatment with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01, ****p < 0.0001.
Figure 3—figure supplement 1
Nonparametric analysis in female mice.
(A) Quantitation of elbow joint extension range of motion in female mice only. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: unpaired, Mann–Whitney U-tests between groups and paired, Wilcoxon signed rank tests between limbs of mice in each group. *p < 0.05, **p < 0.01, ****p < 0.0001.
Figure 4
Pharmacologic myostatin (MSTN) inhibition preserves longitudinal muscle growth of denervated muscles in neonatal female mice.
(A) Representative differential interference contrast (DIC) images of sarcomeres, and (B) quantitation of sarcomere length showed that MSTN inhibition preserves sarcomere length of denervated muscles after neonatal denervation in female mice, whereas the sarcomeres of denervated muscles in male mice remain overstretched. (C) Sarcomere length on the neonatal brachial plexus injury (NBPI) side is normalized to the contralateral side to generate a sarcomere length ratio. This normalized sarcomere length between control and NBPI limbs further confirmed that MSTN inhibition improves functional length of denervated muscles only in female mice. Data are presented as mean ± standard deviation (SD), n = 7–10 independent mice. Statistical analyses: (B) three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons, (C) two-way ANOVA for sex and treatment with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bar: 10 µm.
Figure 5
Sex-specific differences in myostatin (MSTN)-dependent contracture formation is not mediated through protein synthesis.
(A) Representative western blots of puromycin incorporation and (B) quantitative analysis of optical densities revealed MSTN inhibition does not further alter the denervation-induced increases in whole-muscle protein synthesis in biceps muscles of both female and male mice. n = 7–10 independent mice. (C) Representative western blots and quantitative analyses of (D) pAkt (Ser473) and (E) total Akt similarly showed that ACVR2B-Fc treatment does not lead to additional increases in activity and translation of Akt after denervation in both sexes. (F) Quantification of the western signal for pAkt normalized to total protein levels further indicated that MSTN inhibition does not alter Akt/mTOR signaling in neonatally denervated muscles. n = 4–6 independent mice. Statistical analyses: (B, D–F) three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01. 7d MOV = adult mouse plantaris muscle that had been subjected to 7 days of mechanical overload.
-
Figure 5—source data 1
Original and uncropped gels for Puromycin (Figure 5A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig5-data1-v2.zip
-
Figure 5—source data 2
Original and uncropped gels for GAPDH (Figure 5A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig5-data2-v2.zip
-
Figure 5—source data 3
Original and uncropped gels for pAkt (Figure 5C).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig5-data3-v2.zip
-
Figure 5—source data 4
Original and uncropped gels for Akt (Figure 5C).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig5-data4-v2.zip
-
Figure 5—source data 5
Original and uncropped gels for GAPDH (Figure 5C).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig5-data5-v2.zip
Figure 6 with 1 supplement
Sex-specific differences in myostatin (MSTN)-dependent contracture formation is mediated through proteasome activity.
(A) Representative western blots of K48-linked polyubiquitin and (B) quantitative analysis of optical densities showed similar levels of ubiquitination in control and denervated biceps muscles of neonatal female and male mice. Despite this, (C) in-depth analyses of optical densities discovered that denervation increases ubiquitination levels of higher molecular weight proteins >40 kDa, (D) but not lower molecular proteins <40 kDa in both sexes. Importantly, MSTN inhibition does not alter levels of K48 polyubiquitination across the different molecular weights after denervation. n = 4–7 independent mice. (E, F) Assessment of proteasome activity in triceps muscles revealed that MSTN inhibition blunts the denervation-induced increase in β5 but not β1 constitutive proteasome activity solely in female mice. n = 7 independent mice. Data are presented as mean ± standard deviation (SD). Statistical analyses: (B–F) three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 7d MOV = adult mouse plantaris muscle that had been subjected to 7 days of mechanical overload.
-
Figure 6—source data 1
Original and uncropped gels for K48 Polyubiquitin (Figure 6A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig6-data1-v2.zip
-
Figure 6—source data 2
Original and uncropped gels for GAPDH (Figure 6A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig6-data2-v2.zip
Figure 6—figure supplement 1
Assessment of muscle-specific ubiquitin ligases.
(A) Representative western blots and quantitative analyses of (B) MuRF1, and (C) Atrogin-1 showed myostatin (MSTN) inhibition does not alter protein levels in denervated (neonatal brachial plexus injury, NBPI) or contralateral triceps muscles. Data are presented as mean ± standard deviation (SD), n = 3 independent mice. (B, C) Three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons. *p < 0.05.
-
Figure 6—figure supplement 1—source data 1
Original and uncropped gels for MuRF1 (Figure 6—figure supplement 1A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig6-figsupp1-data1-v2.zip
-
Figure 6—figure supplement 1—source data 2
Original and uncropped gels for Atrogin-1 (Figure 6—figure supplement 1A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig6-figsupp1-data2-v2.zip
-
Figure 6—figure supplement 1—source data 3
Original and uncropped gels for GAPDH (Figure 6—figure supplement 1A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig6-figsupp1-data3-v2.zip
Figure 7
Sex-specific differences in myostatin (MSTN)-mediated proteostasis dysregulation occurs independent of Smad2/3 signaling.
(A) Representative western blots and quantitative analyses of (B) pSmad2, (C) total Smad2, (E) pSmad3, and (F) total Smad3 revealed that ACVR2B-Fc treatment does not blunt the denervation-induced increase in activity and translation of Smad2 and Smad3 in triceps muscles of both sexes. Quantification of the western signal for (D) pSmad2 and (G) pSmad3 normalized to total protein levels further indicated that MSTN inhibition does not alter Smad2/3 signaling in neonatally denervated muscles. n = 3–6 independent mice. Data are presented as mean ± standard deviation (SD). Statistical analyses: (B–G) three-way analysis of variance (ANOVA) for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01.
-
Figure 7—source data 1
Original and uncropped gels for pSmad2 (Figure 7A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig7-data1-v2.zip
-
Figure 7—source data 2
Original and uncropped gels for Smad2 (Figure 7A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig7-data2-v2.zip
-
Figure 7—source data 3
Original and uncropped gels for pSmad3 (Figure 7A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig7-data3-v2.zip
-
Figure 7—source data 4
Original and uncropped gels for Smad3 (Figure 7A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig7-data4-v2.zip
-
Figure 7—source data 5
Original and uncropped gels for GAPDH (Figure 7A).
- https://cdn.elifesciences.org/articles/81121/elife-81121-fig7-data5-v2.zip
Figure 8
Proteasome inhibition with bortezomib prevents contractures and restores proteostasis preferentially in denervated muscles of neonatal male mice.
(A) Schematic depiction of bortezomib treatment and assessment of outcomes at 4, 8, or 12 weeks post-neonatal brachial plexus injury (NBPI). (B, C) Continuous bortezomib treatment preferentially prevents elbow and shoulder contractures in male mice throughout postnatal development and into skeletal maturity (n = 3–10 independent mice). (D) Despite this, long-term bortezomib does not confer sex-specific improvements in longitudinal muscle growth, as sarcomere length was preserved in denervated brachialis muscles of both female and male mice (n = 3–10 independent mice). (E–H) As opposed to myostatin (MSTN) inhibition, the rescue in long-term contractures with continuous bortezomib treatment in male mice at 8 and 12 weeks post-NBPI is associated with a decrease in β1 proteasome subunit activity, rather than β5 activity of denervated biceps muscles (n = 3 independent mice). In (B, C), elbow and shoulder contracture severity is calculated as the difference in passive elbow extension and shoulder rotation, respectively, between the denervated (NBPI) side and the contralateral control side. In (D), sarcomere length on the NBPI side is normalized to the contralateral side to generate a sarcomere length ratio. Data are presented as mean ± standard deviation (SD). Statistical analyses: (B–D) two-way analysis of variance (ANOVA) for sex and treatment with a Bonferroni correction for multiple comparisons at each time point, (E–H) three-way ANOVA for sex, treatment, and denervation (repeated measures between forelimbs) with a Bonferroni correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. This figure is generated from primary data reported in Goh et al., 2021.
Tables
Key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Biological sample (CD-1 IGS mouse) | Mouse | Charles River | Strain code 022 | |
| Peptide, recombinant protein | ACVR2B-Fc | https://doi.org/10.1073/pnas.0505996102; https://doi.org/10.1073/pnas.1206410109 | Dr. Se-Jin Lee (The Jackson Laboratory) | |
| Chemical compound, drug | Bortezomib | https://doi.org/10.1096%2Ffj.202002194 | Sigma-Aldrich #5043140001 |
Additional files
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Sex-specific role of myostatin signaling in neonatal muscle growth, denervation atrophy, and neuromuscular contractures
eLife 11:e81121.
https://doi.org/10.7554/eLife.81121
